Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | BCL3 | P20749 | 2/20 | 0.48 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.46 |
| ▸ | KDR | P35968 | 4/20 | 0.46 |
| ▸ | KIT | P10721 | 3/20 | 0.46 |
| ▸ | MAP2K1 | Q02750 | 4/20 | 0.45 |
| ▸ | MAP2K2 | P36507 | 2/20 | 0.45 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.44 |
| ▸ | TLK2 | Q86UE8 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6035311 | 0.93 | KMT2A (0.49) | CYP1A2CYP2D6CYP2C9PDGFRBKDR | |
| SCHEMBL6035676 | 0.93 | CYP1A2 (0.49) | CYP1A2CYP2D6CYP2C9BCL3PDGFRB | |
| SCHEMBL6036039 | 0.92 | CYP1A2 (0.51) | CYP1A2CYP2D6CYP2C9BCL3PDGFRB | |
| SCHEMBL6035287 | 0.91 | BCL3 (0.59) | BCL3PDGFRBKDRKITKMT2A | |
| SCHEMBL8169156 | 0.91 | KMT2A (0.56) | BCL3PDGFRBKDRKITNPSR1 | |
| SCHEMBL6035353 | 0.87 | MAP2K1 (0.50) | CYP2D6CYP2C9BCL3PDGFRBKDR | |
| SCHEMBL6035410 | 0.86 | MKNK2 (0.45) | CYP1A2CYP2D6CYP2C9PDGFRBKDR | |
| SCHEMBL6035749 | 0.84 | MAP2K1 (0.59) | CYP1A2CYP2D6CYP2C9PDGFRBMAP2K1 | |
| SCHEMBL6035719 | 0.84 | BCL3 (0.55) | CYP1A2CYP2D6CYP2C9BCL3KMT2A | |
| SCHEMBL6035461 | 0.84 | MAP2K1 (0.55) | MAP2K1MAP2K2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0993437-B1 | 2-(4-BROMO OR 4-IODO PHENYLAMINO) BENZOIC ACID DERIVATIVES AND THEIR USE AS MEK INHIBITORS | WARNER LAMBERT CO (US) | 2006-11-08 | — | — | EP | claimed |
| US-6972298-B2 | Method of treating or inhibiting neutrophil chemotaxis by administering a MEK inhibitor | WARNER-LAMBERT COMPANY (US) | 2005-12-06 | — | — | US | claimed |
| EP-1140291-B1 | COMBINATION CHEMOTHERAPY COMPRISING A MITOTIC INHIBITOR AND A MEK INHIBITOR | WARNER LAMBERT CO (US) | 2005-11-23 | — | — | EP | claimed |
| EP-1140062-B1 | TREATMENT OF ASTHMA WITH MEK INHIBITORS | WARNER LAMBERT CO (US) | 2005-04-06 | — | — | EP | claimed |
| US-20040171632-A1 | Combination chemotherapy | GOWAN RICHARD CARLETON (US) | 2004-09-02 | — | — | US | claimed |
| US-6696440-B1 | ADMINISTERING MITOGEN ACTIVATED PROTEIN KINASE(MEK) INHIBITORS COMPRISING SECONDARY CARBOCYCLIC AMINES, AS ANTIASTHMATIC AGENTS | WARNER-LAMBERT COMPANY | 2004-02-24 | — | — | US | claimed |
| US-20030149015-A1 | 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives | BARRETT STEPHEN DOUGLAS (US) | 2003-08-07 | — | — | US | claimed |
| US-20030055095-A1 | Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor | BARAGI VIJAYKUMAR M (US) | 2003-03-20 | — | — | US | claimed |
| EP-1262176-A1 | Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor | WARNER-LAMBERT COMPANY (US) | 2002-12-04 | — | — | EP | claimed |
| JP-2002532414-A | — | — | 2002-10-02 | — | — | JP | claimed |
| US-6251943-B1 | 2-(2-AMINO-3-METHOXYPHENYL)4-OXO-4H-(1)BENZOPYRAN A MEK INHIBITOR FOR THE TREATMENT OR PREVENTION OF SEPTIC SHOCK | WARNER-LAMBERT COMPANY | 2001-06-26 | — | — | US | claimed |
| WO-2000035435-A9 | USE OF A MEK INHIBITOR FOR PREVENTING TRANSPLANT REJECTION | WARNER LAMBERT CO (US) | 2001-03-22 | — | — | WO | claimed |
| WO-2000037141-A9 | COMBINATION CHEMOTHERAPY | WARNER LAMBERT CO (US) | 2000-12-07 | — | — | WO | claimed |
| WO-2000040235-A2 | TREATMENT OF ASTHMA WITH MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2000-07-13 | — | — | WO | claimed |
| WO-2000037141-A1 | COMBINATION CHEMOTHERAPY | WARNER-LAMBERT COMPANY (US) | 2000-06-29 | — | — | WO | claimed |
| WO-2000035435-A1 | USE OF A MEK INHIBITOR FOR PREVENTING TRANSPLANT REJECTION | WARNER-LAMBERT COMPANY (US) | 2000-06-22 | — | — | WO | claimed |
| WO-2000035436-A2 | TREATMENT OF ARTHRITIS WITH MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2000-06-22 | — | — | WO | claimed |
| EP-0993437-A1 | 2-(4-BROMO OR 4-IODO PHENYLAMINO) BENZOIC ACID DERIVATIVES AND THEIR USE AS MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2000-04-19 | — | — | EP | claimed |
| WO-1999001421-A1 | 2-(4-BROMO OR 4-IODO PHENYLAMINO) BENZOIC ACID DERIVATIVES AND THEIR USE AS MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1999-01-14 | — | — | WO | claimed |
| WO-1998037881-A1 | METHOD OF TREATING OR PREVENTING SEPTIC SHOCK BY ADMINISTERING A MEK INHIBITOR | WARNER LAMBERT COMPANY (US) | 1998-09-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149015-A1 | 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives | BCOR, BCL6, CBR1 | CYP1A2 796/4885CYP2D6 734/4885CYP2C9 1208/4885 |
| US-20040171632-A1 | Combination chemotherapy | BUB1B, BUB1, PLK1 | CYP1A2 2492/4885CYP2D6 2294/4885CYP2C9 3298/4885 |
| US-20030055095-A1 | Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor | MMP8, SERPINB1, CXCR2 | CYP1A2 3397/4885CYP2D6 3261/4885CYP2C9 3749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.